•  
  •  
  •  
  •  

2026-08-14 02:55:24

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  INE010B01027

Research

  • Quant Pick - Cadila Healthcare - ICICI Direct

Stock Report

  • Zydus Lifesciences Reports Q1 FY27 Results: Operational Revenue Up 22% to ₹80,170 Million
  • Zydus launches REVAHALE™, India's first once-daily nebulised LAMA for COPD
  • Zydus Lifesciences Ltd receives EIR from the USFDA for its injectable facility with VAI classification
  • Zydus signs MoU with Apollo Hospitals to expand access to the Shield™ Multi-Cancer Detection test (MCD) in India
  • Zydus Lifesciences and Sunshine Healthcare announce JV to strengthen pharmaceutical manufacturing in Sri Lanka
  • Zydus announces the successful completion of acquisition of Assertio Holdings
  • Zydus Therapeutics receives USFDA priority review to NDA for Saroglitazar
  • Zydus Lifesciences Limited Financial Performance for Q4 & Full Year FY26
  • USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad
  • Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate
  • Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India
  • Zydus launches Aerolife Mini™, to simplify inhaler use for asthma and COPD patients
  • Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India
  • Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India
  • Zydus' new drug discovery, 'Desidustat' licensed to China Medical System Holdings receives approval from NMPA of China
  • Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg
  • Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor Diasens™ and GlucoLive™
  • Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg
  • Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing
  • Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry
  • Closure of USFDA inspection at Zydus' Injectable plant at Ahmedabad
  • Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025